News
EU approves AstraZeneca’s Calquence in combo with venetoclax, with or without obinutuzumab to treat adult patients with previously untreated CLL: Cambridge, UK Saturday, June 7, ...
AstraZeneca (AZ) has announced that its fixed-duration Calquence (acalabrutinib)-based regimens have been approved by the ...
"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...
Drugmaker AstraZeneca said on Friday that it had received approval from the European Commission for fixed-duration regimens ...
AstraZeneca (LSE: AZN) has received European approval for a fixed-duration regimen of Calquence (acalabrutinib) in ...
Hosted on MSN8mon
AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded UseAstraZeneca AZN announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the expanded use of Calquence (acalabrutinib) in mantle cell lymphoma (MCL).
Hosted on MSN11mon
AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression In Patients With Certain Type Of Blood CancerAstraZeneca Plc (NASDAQ:AZN) released data from the ECHO Phase 3 trial of Calquence (acalabrutinib) plus bendamustine and rituximab compared to standard-of-care chemoimmunotherapy (bendamustine ...
WILMINGTON, Del., June 16, 2024--(BUSINESS WIRE)--Positive results from the ECHO Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with bendamustine and rituximab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback